Latest Clinical Evidence Presented at APWCA’s Wound Week™ 2022 Illustrates the Significant …

Clinical Utility of the MolecuLight Point-of-Care Imaging Platform
PRESS RELEASE
February 24, 2022

Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (February 24, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 8 Clinical Posters and a Presentations and a Hands-On Workshop at the American Professional Wound Care Association’s (APWCA) Wound Week™, held from February 24 – 27, 2022 in Philadelphia, PA. Wound Week is a leading multidisciplinary meeting of wound care professionals that presents cutting-edge clinical findings and best practices presented by its expert faculty.

“We are thrilled with the significant number of presentations and posters at Wound Week showing the impressive results derived from MolecuLight point-of-care devices,” says Anil Amlani, MolecuLight’s CEO. “The clinical insights that are informed by the MolecuLight platform span the wound care continuum, including wound cleansing and hygiene, antimicrobial stewardship, detection of wound-related cellulitis and surgical site infections. The outcomes presented in these studies illustrate the significant clinical improvements to wound care provided to clinicians by the MolecuLightplatform”.

The 8 clinical posters and the presentation featuring the MolecuLight i:X at Wound Week 2022 are as follows:

Posters by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center and Hyperbarics, Lake Success NY) include:

• Wound Hygiene: Which Cleansing Agents and Techniques Are Most Effective?
   Download poster
• 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates
   Download poster

Posters by Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service, Madigan Army Medical Center, Joint Base Lewis-McChord, WA) include:

• Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging
   Download poster
• Guidelines for point-of-care fluorescence imaging for detection of wound bacterial burden based on Delphi consensus
   Download poster

Posters by Dr. Thomas Serena (SerenaGroup Research Foundation, Cambridge, MA) include:

• Reliance on Clinical Signs & Symptoms of Bacterial Burden in Chronic Wounds Leads to the Misuse of Antimicrobials: Analysis of the FLAAG Clinical Trial
   Download poster
• Point-of-care fluorescence imaging enhances detection of high bacterial burden in surgical site wounds
   Download poster
• Are Semi-Quantitative Clinical Cultures Inadequate? Comparison to Quantitative Analysis of 1053 Bacterial Isolates from 350 Wounds
   Download poster
• An image is worth 10,000 microbes: How fluorescence imaging augments IWGDF criteria for detection of bacterial burden in diabetic foot ulcers
   Download poster

The Clinical Presentations citing the MolecuLight point-of-care device is:

• All That Glows is Not Good (Innovative Technologies: What’s in the Pipeline?)  by Dr. Oropallo on Sat., Feb. 26, 2022, 9:00 – 10:00 am in the Commonwealth Room

In addition to the clinical posters and presentations at Wound Week,, the MolecuLight i:X^® and DX™ imaging devices will be demonstrated at the Hands-On Workshop on Thursday, February 24^th from 1:30 pm – 5:30 pm in the Regency B Ballroom. They will also be available for demonstration in the MolecuLight booth #36 in the Exhibit Hall at the Loews, Philadelphia, PA.

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X^® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement.  MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT^® codes for physician work to perform “fluorescence wound imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

For more information, contact: